Resistell
Basel, Switzerland · Founded 2018 · $13.1M raised
- Headquarters
- Basel
- Employees
- 11–50
- Founded
- 2018
- Business Model
- B2B
- Website
- resistell.com
- Total Funding
- $13.1M
- Last Round
- $9.2M Series BDec 2022
- Rounds
- 2
About
Resistell is a Swiss medtech company based in Basel that has commercialized a nanomotion-based rapid antibiotic susceptibility testing (AST) device, technology invented at EPFL's Laboratory of Physics of Living Matter. Founded in 2018 as a spin-off from the École Polytechnique Fédérale de Lausanne, Resistell's diagnostic platform helps clinicians identify effective antibiotics for bacterial infections such as sepsis faster than traditional culture-based methods, addressing the growing threat of antimicrobial resistance (AMR).
Summary
Resistell is a Biotech company based in Basel, Switzerland, founded in 2018. It has raised $13.1M in total across 2 rounds, most recently a $9.2M Series B round in Dec 2022. Investors include OCCIDENT, European Innovation Council Fund and TRUMPF Venture.
Sign up to view the funding chart
Create a free account — you'll get 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...